Latest News
Philips Launches QuickClear Mechanical Thrombectomy System for Blood Clot Removal
Tuba Khan
September 25, 2020
Shots: Royal Philips has expanded its peripheral vascular disease portfolio with the launch of the QuickClear mechanical thrombectomy system. The system features an all-in-one aspiration pump and catheter for the removal of blood clots from
Medtronic Evaluates Insertable Cardiac Monitor to Identify Patients at High Risk of Worsening Heart Failure
Tuba Khan
September 25, 2020
Shots: Medtronic enrolls the first patient in the ALLEVIATE-HF clinical trial assessing the ability of its Reveal LINQ ICM in identifying patients at high risk of worsening HF. The study will enroll ~300 patients at
Roche’s Polivy (polatuzumab vedotin) Receives Health Canada’s Approval For R/R Diffuse Large B Cell Lymphoma
Tuba Khan
September 25, 2020
Shots: Health Canada, under (NOC/c) policy, has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL, who are not eligible for ASCT and prior
Novavax Initiates P-III Study of its COVID-19 Vaccine in the UK
Tuba Khan
September 25, 2020
Shots: Novavax has initiated a P-III study assessing the efficacy, safety, and immunogenicity of NVX-CoV2373 vs PBO in Matrix-M in up to 10,000 individuals aged 18-84yrs. with/out relevant comorbidities, over the next 4-6wks. Half the
Accord Launches Zercepac (biosimilar, trastuzumab) in the UK
Tuba Khan
September 25, 2020
Shots: Accord launches Zercepac as s a biosimilar referencing Herceptin in the UK, following the EC’s approval in Jul’2020. The EC’s approval is based on a series of robust studies including comparative quality studies, pre/
IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations
Tuba Khan
September 24, 2020
Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM,
Pear Therapeutics Reports the Availability of its Prescription Digital Therapeutics to Wellpath Community Care Centers
Tuba Khan
September 24, 2020
Shots: reSET and reSET-O are the 1st US FDA authorized PDTs for patients (aged ≥ 18 yrs.) with substance use disorder and opioid use disorder. The availability of PDT’s with outpatient care will elevate the
Novartis and Siemens Collaborate to Develop Blood Tests for Multiple Sclerosis
Tuba Khan
September 24, 2020
Shots: The companies enter in a master agreement to design, develop, and commercialize diagnostic tests for therapies Novartis’ therapeutic pipeline The collaboration will initially focus on the development of serum neurofilament light chain (NfL) immunoassay
J&J Initiates Global P-III Clinical Study of its COVID-19 Vaccine
Tuba Khan
September 24, 2020
Shots: The initiation of the ENSEMBLE trial follows positive interim results of P-I/IIa study demonstrating the safety and immunogenicity of JNJ-78436735 following a single vaccination. The results have been submitted to medRxiv and expected to
